Oncopeptides AB (publ) (ONCO) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi everyone, and welcome to the presentation of Oncopeptides report for the first quarter of 2025. This is our standard disclaimer. I'm Sofia Hegis, CEO of Oncopeptides, and I'm joined as always by our CFO, Henrik Bergentoft, who will walk you through the financials. But let's begin by highlighting some key developments this quarter. The first quarter was a strong start to the year. Despite some headwinds in terms of weaker euro, which we sell in, compared to the Swedish krona, which we report in, and some seasonal effects that temporarily postpone treatments for certain patients, we delivered net sales of 13.3 million SEK. That means we almost tripled our sales compared to Q1 last year and see a 34% increase compared to Q4 of 2024. This growth was driven by continued traction in Germany and Spain while we are off to a good start in Italy. I will come back to more detailed updates on all of our key markets. Our cash position at the end of the quarter was 107 million SEK and Henrik will cover the financials in detail soon. Important to note is that we remain on track to reach cash flow positivity by the end of 2026. Our key milestone during the quarter was the positive reimbursement decision for PEPAXG in Italy that was officially published. Shortly thereafter, we received our first hospital order in the country, a significant commercial milestone ahead of our time plan. Another achievement was that the FDA lifted the clinical hold on OPD5, an important step forward for our future US ambitions. I'll return to these topics shortly, but first over to Henrik for the financial update. Thank you, Sofia. So this financial summary highlights the company's performance across several key metrics. Notably, net sales have shown significant growth with a 34% increase compared to ...